» Articles » PMID: 18376417

Growth Hormone, IGF-I and Insulin and Their Abuse in Sport

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2008 Apr 1
PMID 18376417
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

There is widespread anecdotal evidence that growth hormone (GH) is used by athletes for its anabolic and lipolytic properties. Although there is little evidence that GH improves performance in young healthy adults, randomized controlled studies carried out so far are inadequately designed to demonstrate this, not least because GH is often abused in combination with anabolic steroids and insulin. Some of the anabolic actions of GH are mediated through the generation of insulin-like growth factor-I (IGF-I), and it is believed that this is also being abused. Athletes are exposing themselves to potential harm by self-administering large doses of GH, IGF-I and insulin. The effects of excess GH are exemplified by acromegaly. IGF-I may mediate and cause some of these changes, but in addition, IGF-I may lead to profound hypoglycaemia, as indeed can insulin. Although GH is on the World Anti-doping Agency list of banned substances, the detection of abuse with GH is challenging. Two approaches have been developed to detect GH abuse. The first is based on an assessment of the effect of exogenous recombinant human GH on pituitary GH isoforms and the second is based on the measurement of markers of GH action. As a result, GH abuse can be detected with reasonable sensitivity and specificity. Testing for IGF-I and insulin is in its infancy, but the measurement of markers of GH action may also detect IGF-I usage, while urine mass spectroscopy has begun to identify the use of insulin analogues.

Citing Articles

Relationship between Serum Sirtuin 1 and Growth Hormone/Insulin-like Growth Factor 1 Concentrations in Children with Growth Hormone Deficiency and Idiopathic Short Stature.

Fedorczak A, Kowalik D, Kopciuch J, Glowacka E, Mikolajczyk K, Tkaczyk M Biomedicines. 2024; 12(7).

PMID: 39062007 PMC: 11274889. DOI: 10.3390/biomedicines12071433.


Metabolic Consequences of Anabolic Steroids, Insulin, and Growth Hormone Abuse in Recreational Bodybuilders: Implications for the World Anti-Doping Agency Passport.

Di Girolamo F, Biasinutto C, Mangogna A, Fiotti N, Vinci P, Pisot R Sports Med Open. 2024; 10(1):28.

PMID: 38536564 PMC: 10973313. DOI: 10.1186/s40798-024-00697-6.


Detection of synthetic analogues of insulin-like growth factor 1 in different biological fluids by liquid chromatography quadrupole time-of-flight mass spectrometry: comparison of different immunoaffinity protocols.

Mazzarino M, Melis I, Quaresima E, Botre F Anal Bioanal Chem. 2023; 415(24):6117-6131.

PMID: 37566232 DOI: 10.1007/s00216-023-04885-3.


Synthetic Peptides in Doping Control: A Powerful Tool for an Analytical Challenge.

Gomez-Guerrero N, Gonzalez-Lopez N, Zapata-Velasquez J, Martinez-Ramirez J, Rivera-Monroy Z, Garcia-Castaneda J ACS Omega. 2022; 7(43):38193-38206.

PMID: 36340120 PMC: 9631397. DOI: 10.1021/acsomega.2c05296.


Bioactive peptides identification and nutritional status ameliorating properties on malnourished rats of combined eel and soy-based tempe flour.

Sabrina N, Rizal M, Nurkolis F, Hardinsyah H, Tanner M, Gunawan W Front Nutr. 2022; 9:963065.

PMID: 36245543 PMC: 9554436. DOI: 10.3389/fnut.2022.963065.


References
1.
Rennie M . Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes?. Br J Sports Med. 2003; 37(2):100-5. PMC: 1724606. DOI: 10.1136/bjsm.37.2.100. View

2.
Healy M, Dall R, Gibney J, Bassett E, Ehrnborg C, Pentecost C . Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J Clin Endocrinol Metab. 2004; 90(2):641-9. DOI: 10.1210/jc.2004-0386. View

3.
Dall R, Longobardi S, Ehrnborg C, Keay N, Rosen T, Jorgensen J . The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab. 2000; 85(11):4193-200. DOI: 10.1210/jcem.85.11.6964. View

4.
Yakar S, Liu J, STANNARD B, Butler A, Accili D, Sauer B . Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999; 96(13):7324-9. PMC: 22084. DOI: 10.1073/pnas.96.13.7324. View

5.
Zenobi P, Graf S, Ursprung H, FROESCH E . Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest. 1992; 89(6):1908-13. PMC: 295890. DOI: 10.1172/JCI115796. View